Trial Profile
A Study Assessing the Association between Baseline Clinical Characteristics and Long-Term Efficacy of Omalizumab (for 5 years) in Patients with Severe Allergic Asthma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 14 Jul 2017 New trial record
- 24 May 2017 Results assessing association between baseline clinical characteristics and efficacy of Omalizumab for 5 years in patients with severe asthma, presented at the 113th International Conference of the American Thoracic Society.